Introduction to Hypersensitivity

Understanding Hypersensitivity Reactions What is Hypersensitivity? Hypersensitivity refers to an exaggerated or inappropriate immune response that damages the body's own tissues and causes clinical symptoms. This is distinct from a normal immune reaction, where the immune system successfully eliminates foreign substances without harming the host. Think of it this way: a normal immune response is like a security guard who stops a threat without breaking anything. A hypersensitivity reaction is like a security guard who stops the threat but inadvertently damages the building in the process. The immune system is overreacting or responding to the wrong target. Understanding which type of hypersensitivity a patient has is clinically important because it directly guides treatment decisions. Additionally, hypersensitivity reactions exist on a spectrum of severity—ranging from mild itching and discomfort (such as seasonal allergies) to life-threatening emergencies (such as anaphylactic shock). Type I Hypersensitivity: The Immediate, IgE-Mediated Response Type I hypersensitivity is the most immediately dangerous form. It occurs when the body mounts a rapid immune response against a harmless substance (called an allergen). The Key Players Type I reactions depend on IgE antibodies binding to receptors on the surface of mast cells and basophils. These are immune cells loaded with inflammatory chemicals like histamine. When an allergen bridges two IgE molecules on a mast cell, it triggers degranulation—meaning the cell releases its chemical payload all at once. Why It's Called "Immediate" These reactions occur within minutes of exposure to the allergen. This rapid timeline makes Type I reactions distinctive: by the time a patient seeks help, the reaction is already underway. Common Clinical Examples Seasonal allergies: Pollen triggers IgE production, leading to sneezing and itchy eyes Allergic asthma: Allergen exposure causes airway constriction Anaphylaxis: The most severe form, where massive histamine release causes airway swelling, dramatic blood pressure drops, and shock Treatment Strategies Antihistamines block histamine receptors on target cells, reducing itching, swelling, and other histamine-mediated symptoms Epinephrine is the emergency treatment for anaphylaxis—it rapidly constricts blood vessels (raising blood pressure), relaxes airway smooth muscle (opening the airway), and reduces further mast cell degranulation Type II Hypersensitivity: Antibody-Mediated Cytotoxic Reactions Type II hypersensitivity occurs when antibodies bind to antigens (targets) on the surface of cells, marking those cells for destruction. The body's own cells become the target. The Key Players IgG or IgM antibodies recognize and bind to antigens displayed on cell surfaces. Once bound, these antibodies trigger two destruction pathways: Complement activation: The antibody-antigen complex activates the complement system, which deposits destructive proteins on the cell surface Cell-mediated cytotoxicity: Natural killer cells and macrophages recognize the antibody-coated cells and destroy them Why Cells Are Damaged The tissue damage in Type II reactions occurs because the immune system is literally destroying cells that display the target antigen. This is fundamentally different from Type I, where the damage is caused by inflammatory chemicals released into the tissue. Timing Type II reactions develop over hours to days as antibodies accumulate and activate destructive mechanisms. This slower timeline distinguishes them from immediate Type I reactions. Common Clinical Examples Hemolytic transfusion reactions: If a patient receives blood with incompatible antigens, the recipient's antibodies attack the donor red blood cells Hemolytic disease of the newborn: Maternal antibodies (usually anti-Rh D) cross the placenta and destroy fetal red blood cells Goodpasture's syndrome: Autoantibodies attack the basement membrane of kidneys and lungs Drug-induced hemolytic anemia: A drug binds to red blood cells, the body makes antibodies against the drug-cell complex, and red blood cells are destroyed Treatment Strategies Removing the offending antigen: Stop the medication, or transfuse compatible blood Suppressing complement activity: Reduces the destructive cascade Immunosuppression: Reduces antibody production in autoimmune forms Type III Hypersensitivity: Immune Complex-Mediated Reactions Type III hypersensitivity results from the deposition of immune complexes—aggregates of antigens bound to antibodies—in tissues. These complexes themselves act as inflammatory triggers. The Key Players When antibodies bind to soluble antigens, they form immune complexes. In small amounts, these are normally cleared by the body. In excess, they deposit in tissues and blood vessel walls. How Tissue Damage Occurs Deposited immune complexes activate complement and attract inflammatory cells. This causes: Inflammation at the site of deposition Vascular damage Tissue injury throughout the affected area This is different from Type II, where specific cells are targeted for destruction. In Type III, the damage is more widespread and based on where complexes happen to deposit. Timing Type III reactions develop over hours to days as immune complexes form and deposit in tissues. Common Clinical Examples Serum sickness: After receiving foreign protein (like antiserum or monoclonal antibodies), antibodies form complexes with the foreign antigen, causing fever, rash, and joint pain Systemic lupus erythematosus (SLE): The body produces autoantibodies against nuclear antigens, forming complexes that deposit in kidneys, joints, and skin Arthus reaction: A localized Type III reaction occurring 4–12 hours after antigen injection, causing redness and swelling at the injection site Treatment Strategies Corticosteroids: Reduce inflammation by suppressing immune cell activation and cytokine production Removing the antigen source: Stop administering the offending medication or protein Supportive care: Managing symptoms while immune complexes are cleared Type IV Hypersensitivity: Delayed T-Cell-Mediated Reactions Type IV hypersensitivity is the only type that does not involve antibodies. Instead, T cells recognize antigens and orchestrate a delayed inflammatory response. This is why it's called "delayed"—there's a lag between exposure and the visible reaction. The Key Players Two types of T cells drive Type IV reactions: CD4⁺ T helper 1 (Th1) cells: Release inflammatory cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor (TNF) CD8⁺ cytotoxic T cells: Directly kill target cells expressing the antigen These cytokines recruit and activate macrophages, which then cause tissue inflammation and damage. How Tissue Damage Occurs The damage mechanisms include: Macrophage activation by Th1 cytokines, causing local inflammation Direct killing of infected or antigen-presenting cells by CD8⁺ T cells Release of toxic compounds from activated macrophages Timing: The Hallmark of Type IV Type IV reactions are distinctly delayed, appearing 24 to 72 hours after antigen exposure. This delayed timeline is the clinical key to identifying Type IV reactions. When a patient develops a reaction days after exposure, think Type IV. Common Clinical Examples Contact dermatitis from poison ivy: T cells recognize urushiol oil (the antigen) and cause skin inflammation and blistering—the rash typically appears 24–48 hours after exposure Positive tuberculin skin test (Mantoux test): Intradermal injection of tuberculin antigen triggers a localized Type IV response in people previously exposed to Mycobacterium tuberculosis—induration peaks at 48–72 hours Drug-induced hypersensitivity: T cells react to drugs or drug metabolites, causing delayed rash or organ inflammation Type 1 diabetes: Autoreactive CD8⁺ T cells attack insulin-producing beta cells in the pancreas Treatment Strategies Corticosteroids: Suppress cytokine production and macrophage activation, reducing inflammation Avoiding the trigger: Identifying and removing exposure to the offending antigen Immunosuppression: In severe cases, more potent agents may be needed Comparing the Four Types: A Quick Reference The four types of hypersensitivity can be challenging to keep straight, so understanding their key differences is essential: Timing is the most important clinical clue: Type I happens in minutes Types II and III happen in hours to days Type IV happens in 24–72 hours (or longer) Immune mechanism distinguishes them: Type I uses IgE antibodies on mast cells Type II uses IgG/IgM antibodies against cell surfaces Type III uses antibody-antigen complexes depositing in tissues Type IV uses T cells, not antibodies Clinical Management Overview Why Identifying the Type Matters Different hypersensitivity types require different treatments. Correctly identifying which type of reaction a patient is experiencing allows clinicians to select the most effective therapy and avoid wasting time on ineffective treatments. Antihistamines for Type I Reactions Antihistamines block histamine receptors on target cells. They are effective for Type I hypersensitivity because histamine is a major mediator of symptoms. However, they are ineffective (and inappropriate) for Types II, III, and IV because tissue damage in those types doesn't rely on histamine. Epinephrine for Anaphylaxis Epinephrine is the emergency drug for anaphylaxis (severe Type I reaction). It works by: Constricting blood vessels (reversing shock) Relaxing airway smooth muscle (opening the airway) Suppressing further mast cell degranulation Epinephrine must be given quickly—delays in administration increase mortality risk. Corticosteroids for Types III and IV Corticosteroids suppress inflammation by inhibiting cytokine production and immune cell activation. They are the mainstay for Type III (immune complex) and Type IV (delayed T-cell) reactions. They are less useful in Type I (where histamine release is the immediate problem) and Type II (where antibody-mediated cytotoxicity is already underway). <extrainfo> Diagnostic Considerations Identifying the type of hypersensitivity guides which laboratory tests and clinical assessments are most useful: For Type I: Skin prick tests, IgE levels, and challenge tests may be performed For Type II: Blood counts, direct antiglobulin test (Coombs test), and complement levels may be measured For Type III: Immune complex levels, complement depletion, and urinalysis (for kidney involvement) are helpful For Type IV: Skin patch testing or delayed intradermal challenges may be used </extrainfo>